Correlation Engine 2.0
Clear Search sequence regions

  • antibodies (4)
  • b cell (3)
  • b cell subsets (2)
  • BAFF (5)
  • donor (1)
  • end- stage renal disease (3)
  • hla (1)
  • HLA T (1)
  • immunoglobulins (2)
  • marrow (1)
  • patients (6)
  • phase (1)
  • pneumonia (1)
  • tonsil (1)
  • Sizes of these terms reflect their relevance to your search.

    B cell-activation factor (BAFF) is critical for B cell maturation. Inhibition of BAFF represents an appealing target for desensitization of sensitized end-stage renal disease (ESRD) patients. We conducted a Phase 2a, single-arm, open-label exploratory study investigating the effect of tabalumab (BAFF inhibitor) in patients with ESRD and calculated panel reactive antibodies (cPRAs) >50%. The treatment period duration was 24 weeks. Eighteen patients received tabalumab, at doses of 240-mg subcutaneous (SC) at Week 0 followed by 120-mg SC monthly for 5 additional months. Patients were followed for an additional 52 weeks. Immunopharmacologic effects were characterized through analysis of blood for HLA antibodies, BAFF concentrations, immunoglobulins, T and B cell subsets, as well as pre- and posttreatment tonsil and bone marrow biopsies. Significant reductions in cPRAs were observed at Weeks 16 (p = 0.043) and 36 (p = 0.004); however, absolute reductions were small (<5%). Expected pharmacologic changes in B cell subsets and immunoglobulin reductions were observed. Two tabalumab-related serious adverse events occurred (pneumonia, worsening of peripheral neuropathy), while the most common other adverse events were injection-site pain and hypotension. Three patients received matched deceased donor transplants during follow-up. Treatment with a BAFF inhibitor resulted in statistically significant, but not clinically meaningful reduction in the cPRA from baseline (NCT01200290, © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.


    M A Mujtaba, W J Komocsar, E Nantz, M D Samaniego, S L Henson, J A Hague, A L Lobashevsky, N G Higgins, M Czader, B K Book, M D Anderson, M D Pescovitz, T E Taber. Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2016 Apr;16(4):1266-75

    PMID: 26780484

    View Full Text